Korean J Urol.  2007 Mar;48(3):233-243. 10.4111/kju.2007.48.3.233.

Medical Management for Benign Prostatic Hyperplasia

• Chung BH

• KMID: 1997119
• DOI: http://doi.org/10.4111/kju.2007.48.3.233

Abstract

The aim of therapy for benign prostatic hyperplasia (BPH) is to improve quality of life by providing symptom relief and an increased maximum flow rate, as well as reduce disease progression and the development of new morbidities. There has been an enormous decline in the popularity of surgery and it is now apparent that medication is the most frequently used treatment for BPH. This has arguably therefore been the most major change in urological clinical practice in the last decade. Currently alpha(1)-adrenoceptor antagonists are the commonest medical therapy, and are thought to act by relaxing prostatic smooth muscle, the neural or so-called 'dynamic' component of BPO. 5alpha-reductase inhibitors are another option for BPH, which reduce prostatic mass and therefore the mechanical or 'static' component of benign prostatic obstruction (BPO). Another group of agents are the phytotherapeutic extracts, which act via various mechanisms, many as yet poorly defined. This review critically assesses existing publications relating to the medical management of BPH.

Keyword

Benign Prostatic Hyperplasia; Medical Management

MeSH Terms

Disease Progression
Muscle, Smooth
Prostatic Hyperplasia*
Quality of Life

Reference

1. Caine M, Perlberg S, Meretyk S. A placebo-controlled double-blind study of the effect of phenoxybenzamine in benign prostatic obstruction. Br J Urol. 1978. 50:551–554.

2. McNeal JE. Origin and evolution of benign prostatic enlargement. Invest Urol. 1978. 15:340–345.

3. Caine M, Raz S, Zeigler M. Adrenergic and cholinergic receptors in the human prostate, prostatic capsule and bladder neck. Br J Urol. 1975. 47:193–202.

4. Bartsch G, Frick J, Ruegg I, Bucher M, Holliger O, Oberholzer M, et al. Electron microscopic stereological analysis of the human prostate and of benign prostatic hyperplasia. J Urol. 1979. 122:481–486.

5. Dunzendorfer U, Jonas D, Weber W. The autonomic innervation of the human prostate. Histochemistry of acetyl-cholinesterase in the normal and pathologic states. Urol Res. 1976. 4:29–31.

6. Furuya S, Kumamoto Y, Yokoyama E, Tsukamoto T, Izumi T, Abiko Y. Alpha adrenergic activity and urethral pressure in prostatic zone in benign prostatic hypertrophy. J Urol. 1982. 128:836–839.

7. Bartsch G, Muller HR, Oberholzer M, Rohr HP. Light microscopic sterological analysis of the normal human prostate and of benign prostatic hyperplasia. J Urol. 1979. 122:487–491.

8. Shapiro E, Hartanto V, Lepor H. Quantifying the smooth muscle content of the prostate using double-immunoenzymatic staining and color assisted image analysis. J Urol. 1992. 147:1167–1170.

9. Minneman KD, Han C, Abel PW. Comparison of alpha 1-adrenergic receptor subtypes distinguished by chlorethylclonidine and WB-4101. Mol Pharmacol. 1988. 33:509–514.

10. Lepor H, Tang R, Meretyk S, Shapiro E. Alpha 1 adrenoceptor subtypes in the human prostate. J Urol. 1993. 149:640–642.

11. Han C, Hollinger S, Theroux TL. Tamsulosin binding to cloned alpha 1 adrenergic receptor subtypes stably expressed in human embryonic kidney 293 cells. Pharmacol Comm. 1994. 5:117.

12. Lepor J, Knapp-Maloney G, Sunshine H. A close titration study evaluating terazosin, a selective, once-a-day alpha-1 blocker for the treatment of symptomatic benign prostatic hyperplasia. J Urol. 1990. 144:1393–1397.

13. Lepor H, Machi G. The relative efficacy of terazosin versus terazosin and flutamide for the treatment of symptomatic BPH. Prostate. 1992. 20:89–93.

14. Chung BH, Chung HJ, Hong SJ. Long-term efficacy and safety of terazosin in the symptomatic treatment of benign prostatic hyperplasia. Korean J Androl. 1999. 17:45–50.

15. Johnson TM 2nd, Jones K, Williford WO, Kutner MH, Issa MM, Lepor H. Changes in nocturia from medical treatment of benign prostatic hyperplasia: secondary analysis of the department of veterans affairs cooperative study trial. J Urol. 2003. 170:145–148.

16. Chung BH, Kim YS, Hong SJ. 12-month follow-up study to evaluate the efficacy and safety of doxazosin GITS in patients with benign prostatic hyperplasia. Korean J Urol. 2005. 46:451–457.

17. Chung BH, Park EK, Hong SJ. The efficacy and safety of doxazocin GITS in patients with benign prostatic hyperplasia. Korean J Urol. 2004. 45:667–673.

18. Andersen M, Dahlstrand C, Hoye K. Double-blind trial of the efficacy and tolerability of doxazosin in the gastrointestinal therapeutic system, doxazosin standard, and placebo in patients with benign prostatic hyperplasia. Eur Urol. 2000. 38:400–409.

19. Gratzke P, Kirby RS. Doxazosin GITS versus regular doxazosin in benign prostatic hyperplasia. Restoring urine flow and sexual function more easily. MMW Fortschr Med. 2000. 142:40.

20. Jardin A, Bensadoun H, Delauche-Cavallier MC, Stalla-Bourdillon A, Attali P. BPHALF Group. Long-term treatment of benign prostatic hyperplasia with alfuzosin; a 24-30 month survey. Br J Urol. 1994. 74:579–584.

21. van Kerrebroec P, Jardin A, van Cangh P, Laval KU. ALFORTI Study Group. Long-term safety and efficacy of a once-daily formulation of alfuzosin 10mg in patients with symptomatic benign prostatic hyperplasia: open-label extension study. Eur Urol. 2002. 41:54–60.

22. Roehrborn CG. Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial. Urology. 2001. 58:953–959.

23. Nickel JC, Elhilali M, Emberton M, Vallancien G. The Alf-One Study Group. The beneficial effect of alfuzosin 10 mg once daily in 'real-life' practice on lower urinary tract symptoms (LUTS), quality of life and sexual dysfunction in men with LUTS and painful ejaculation. BJU Int. 2006. 97:1242–1246.

24. Abrams PH, Schulman CC, Vaage S. The European Tamsulosin Study Group. Tamsulosin, a selective α1c-adrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic 'obstruction' (symptomatic BPH). Br J Urol. 1995. 76:325–336.

25. Schulman CC, Cirtvriend J, Jonas U, Lock TM, Vaage S, Speakman MJ. Tamsulosin, the first prostate-selective alpha1A-adrenoceptor antagonist. analysis of a multinational, multicentre, open-label study assessing the long-term efficacy and safety in patients with benign prostatic obstruction (symptomatic BPH). Eur Urol. 1996. 29:145–154.

26. Lee ES, Lee SW. Effect of tamsulosin, a selective α1A-adrenoreceptor antagonists, in benign prostatic hyperplasia. Korean J Urol. 1997. 38:158–166.

27. Joung JY, JPark JK. The role of alpha 1 (A) adrenoceptor antagonist tamsulosin for the treatment of patients with benign prostatic hyperplasia: the effect on lower urinary tract symptoms and nocturia. Korean J Urol. 2006. 47:1–6.

28. Park CH, Chang HS, Oh BY, Kim HJ, Sul CK, Chung SK, et al. One year long-term evaluation of tamsulosin HCL (0.2mg) in lower urinary tract symptoms suggestive of benign prostatic obstruction: analysis of a Korean, multicenter, single-blind study. J Korean Continence Soc. 2004. 8:1–8.

29. Lowe FC. Coadministration of tamsulosin and three antihypertensive agents in patients with benign prostatic hyperplasia; pharmacodynamic effect. Clin Ther. 1997. 19:730–742.

30. Kaplan SA, Kaplan NM. Alpha-blockade: monotherapy for hypertension and benign benign prostatic hyperplasia. Urology. 1996. 48:541–550.

31. Harris GW. Pituitary-hypothalmic mechanisms. AMA Arch Neurol Psychiatry. 1955. 73:124–126.

32. Steiner NN. Clinical pharmacokinetics and phamarcodynamics of finasteride. Clin Pharmacokinet. 1996. 30:16–27.

33. Peters DH, Sorkin EM. Finasteride. A review of its potential in the treatment of benign prostatic hyperplasia. Drugs. 1993. 46:177–208.

34. McConnell JD, Bruskewits R, Walsh P, Andriole A, Lieber M, Holtgrewe HL, et al. Finasteride Long-Term Efficacy and Safty Study Group. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med. 1998. 338:557–563.

35. Roehrborn CG, Bruskewitz R, Nickel JC, McConnell JD, Saltzman B, Gittelman MC, et al. Sustained decreased in incidence of acute urinary retention and surgery with finasteride for 6 years in men with benign prostatic hyperplasia. J Urol. 2004. 171:1194–1198.

36. Clark RV, Hermann DJ, Gabriel H, Wilson TH, Morrill BB, Hobbs S. Effective supression of dihydrotestosterone (DHT) by GI198745, a novel, dual 5alpha-reductase inhibitor. J Urol. 1999. 161:268.

37. Oh SH, Oh BR, Ryu SB. Effect of finasteride on sexual function in patients with benign prostatic hyperplasia. Korean J Urol. 2002. 43:611–618.

38. Choi WS, Moon KH. The effect of finasteride, tamsulosin and doxazosin therapy on sexual function in patients with benign prostatic hyperplasia. Korean J Urol. 2004. 45:777–782.

39. Lynch TH. Doxazosin and finasteride alone or in combination: the PREDICT study. BJU Int. 2003. 91:591–592.

40. McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, et al. The long-term effect of doxazoxin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003. 349:2387–2398.

41. Barkin J, Guimaraes M, Jacobi G, Pushkar D, Taylor S, van Vierssen Trip OB. Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5alpha-reductase inhibitor dutasteride. Eur Urol. 2003. 44:461–466.

42. Jeong DH, Park YI. Clinical experience of symptomatic management of BPH with terazosin, doxazosin or combination of terazosin and finasteride. Korean J Urol. 1998. 39:772–776.

43. Noh JH, Oh BY, Park YI. The efficacy of combination therapy of 5α-reductase inhibitor and α1-adrenergic blocker in benign prostate hyperplasia. Korean J Urol. 1998. 39:1190–1196.

44. Cho SH, Lee SK. The experience with combination of finasteride and tamsulosin on benign prostatic hyperplasia. Korean J Urol. 2003. 44:1110–1115.

45. Kim CI, Chang HS, Kim BK, Park CH. Long-term results of medical treatment in benign prostatic hyperplasia. Urology. 2006. 68:1015–1019.

46. Douchamps J, Derenne F, Stockis A, Gangji D, Juvent M, Herchuelz A. The pharmacokinetics of oxybutynin in man. Eur J Clin Pharmacol. 1988. 35:515–520.

47. The Korean Prostate Society. Textbook of benign prostatic hyperplasia. 2004. 1st ed. Seoul: Ilchokak Publishing Inc;269–270.

48. Braverman AS, Ruggieri MR, Pontari MA. The M2 muscarinic receptor subtype mediates cholinergic bladder contraction in patients with neurogenic bladder dysfunction. J Urol. 2001. 165:Suppl 36. 2498–2499.

49. Fitzpatrick JM, Lynch TH. Phytotherapeutic agents in the management of symptomatic benign prostatic hyperplasia. Urol Clin North Am. 1995. 22:407–412.

50. The Korean Prostate Society. Textbook of benign prostatic hyperplasia. 2004. 1st ed. Seoul: Ilchokak Publishing Inc;259–260.